The news of Citigroup maintaining a Buy rating on Sarepta Therapeutics is positive for the stock. However, the lowering of the price target from $204 to $161 may create some uncertainty among investors, potentially offsetting the positive sentiment. As a result, the short-term impact on the stock price is expected to be neutral.